Viking Therapeutics VKTX Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's operating lease right-of-use asset amortization?
- Viking Therapeutics (VKTX) reported operating lease right-of-use asset amortization of $85K in Q1 2026.
- How has Viking Therapeutics's operating lease right-of-use asset amortization changed year-over-year?
- Viking Therapeutics's operating lease right-of-use asset amortization decreased by 23.4% year-over-year, from $111K to $85K.
- What is the long-term trend for Viking Therapeutics's operating lease right-of-use asset amortization?
- Over 3 years (2022 to 2025), Viking Therapeutics's operating lease right-of-use asset amortization has grown at a 14.0% compound annual growth rate (CAGR), from $291K to $431K.